Novartis says mid-stage pipeline is setting up strong growth spurtNovartis kicked off its R&D update in London this morning by pledging to bring at least 10 drugs Share XNovartis says mid-stage pipeline is setting up strong growth spurthttps://pharmaphorum.com/news/novartis-says-mid-stage-pipeline-is-setting-up-strong-growth-spurt/
Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-upTwo biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for Share XNeurocrine and Xenon agree $1.75bn epilepsy R&D tie-uphttps://pharmaphorum.com/news/neurocrine-and-xenon-agree-1-75bn-epilepsy-rd-tie-up/
Astellas buys gene therapy company for $3bnAstellas has announced it will be acquiring gene therapy specialists Audentes Therapeutics for a total equity value of Share XAstellas buys gene therapy company for $3bnhttps://pharmaphorum.com/news/astellas-acquires-gene-therapy-company-for-3bn/
Roche trumpets data for Soliris rival in NMOSD after US, EU filingsRoche has continued to build the case for satralizumab, its experimental therapy for rare disease neuromyelitis optica spectrum Share XRoche trumpets data for Soliris rival in NMOSD after US, EU filingshttps://pharmaphorum.com/news/roche-trumpets-data-for-soliris-rival-in-nmosd-after-us-eu-filings/
FDA tags psilocybin drug as clinical depression Breakthrough TherapyThe FDA has tagged psilocybin, the illegal psychoactive compound found in ‘magic mushrooms’, as a potential breakthrough treatment Share XFDA tags psilocybin drug as clinical depression Breakthrough Therapyhttps://pharmaphorum.com/news/fda-tags-psilocybin-drug-as-clinical-depression-breakthrough-therapy/
ViGeneron to develop next-gen eye gene therapies after funding roundGermany’s ViGeneron is to advance development of its next-generation ophthalmology gene therapy pipeline after a series A financing Share XViGeneron to develop next-gen eye gene therapies after funding roundhttps://pharmaphorum.com/news/vigeneron-to-develop-next-gen-eye-gene-therapies/
Mereo’s brittle bone drug likely to shrug off phase 2b fail, say analystsMereo’s drug candidate for brittle bone disease missed its primary endpoint in a recent phase 2b study, but Share XMereo’s brittle bone drug likely to shrug off phase 2b fail, say analystshttps://pharmaphorum.com/news/mereos-brittle-bone-drug-likely-to-shrug-off-phase-2b-fail-say-analysts/
AZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugsStem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will Share XAZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugshttps://pharmaphorum.com/news/az-and-novoheart-collaborate-on-heart-in-a-jar-to-d/
Another NASH setback as CymaBay drops seladelparCymaBay Therapeutics has scrapped two mid-stage trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), Share XAnother NASH setback as CymaBay drops seladelparhttps://pharmaphorum.com/news/another-nash-setback-as-cymabay-drops-seladelpar/
BMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanomaBristol-Myers Squibb’s checkpoint inhibitor combination of Opdivo and low-dose Yervoy is key to its future plans in immuno-oncology, Share XBMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanomahttps://pharmaphorum.com/news/bms-opdivo-yervoy-combo-hits-a-snag-in-adjuvant-melanoma/
Allergan builds case for migraine drug ubrogepant as FDA verdict nearsAllergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved Share XAllergan builds case for migraine drug ubrogepant as FDA verdict nearshttps://pharmaphorum.com/news/allergan-builds-case-for-migraine-drug-ubrogepant-as-fda-verdict-nears/
Biofabri’s TB vaccine collaboration presses ahead with vaccine trialA collaboration between Biofabri, a non-profit organisation, and academics from South Africa are pressing ahead with clinical development Share XBiofabri’s TB vaccine collaboration presses ahead with vaccine trialhttps://pharmaphorum.com/news/biofabris-tb-vaccine-collaboration-presses-ahead-with-vaccine-trial/
CRISPR trials yield encouraging data in blood disordersData on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta Share XCRISPR trials yield encouraging data in blood disordershttps://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/
Novo bolsters R&D pipeline with RNAi therapies from DicernaNovo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to Share XNovo bolsters R&D pipeline with RNAi therapies from Dicernahttps://pharmaphorum.com/news/novo-bolsters-rd-pipeline-with-rnai-therapies-from-dicerna/
Merck/Bayer set to challenge Novartis in heart failure after phase 3 trial successMerck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, Share XMerck/Bayer set to challenge Novartis in heart failure after phase 3 trial successhttps://pharmaphorum.com/news/merck-bayers-heart-failure-drug-on-target-at-phase-3/
Alkermes bolts on Rodin Therapeutics to bulk up thin pipelineAlkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative Share XAlkermes bolts on Rodin Therapeutics to bulk up thin pipelinehttps://pharmaphorum.com/news/alkermes-bolts-on-rodin-therapeutics-to-bulk-up-thin-pipeline/
Roche increases IPF presence with $1.39bn Promedior buyRoche has agreed to buy US biotech Promedior, and a portfolio of drugs including a promising molecule for Share XRoche increases IPF presence with $1.39bn Promedior buyhttps://pharmaphorum.com/news/roche-looks-to-increase-ipf-presence-with-1-39bn-promedior-buy/
Allergan bolsters aesthetics pipeline with Exicure hair loss dealAllergan hasn’t pressed pause on business development in the build-up to its $63 billion buyout by AbbVie, and Share XAllergan bolsters aesthetics pipeline with Exicure hair loss dealhttps://pharmaphorum.com/news/allergan-bolsters-aesthetics-unit-with-exicure-hair-loss-deal/
